Abstract
Aim. To assess the relationship between plasma chitotiosidase (CHIT) level and mortality in hospitalized patients with COVID-19.
Materials and methods. 347 hospitalized patients with COVID-19 were enrolled in our single-center cohort prospective observational study. On the first day of hospitalization the patients were assessed by the level of CHIT in the venosus blood to addition to default laboratory examinations. The primary endpoint was all-cause death. The survival after hospital discharge were assessed via phone calls on 90 and 180 days since inclusion to the study (NCT04752085).
Results. Our study included 347 patients. The first symptoms appeared in 7 days [5; 7] before hospitalization; 283 (84.3%) patients had less than 50% of the involvement of the lung tissue to the inflammation process (CT 02); 36 (10.4%) patients had died since the start of our investigation; 30 (83.3%) of them died during hospitalization, others -no later than 60 days; 68 (19%) people didnt answer during phone call. The survivor's activity of the enzyme in the deceased was significantly lower in compare to deceased patients (90.5 [40.2; 178.0] nmol/h/mL vs 180.0 [77.2; 393.2] nmol/h/mL; p=0.001). Survivor of the patients with a higher level of the activity of the CHIT (more than 171 nmol/h/mL) was statically significantly lower.
Conclusion. Rising of the CHIT's activity more than 171 nmol/h/mL might be an early independent predictor of the bad prognosis of the patients, who were hospitalized with COVID-19 infection.
Subject
General Medicine,Endocrinology, Diabetes and Metabolism,History,Family Practice,General Medicine
Reference12 articles.
1. «Профилактика, диагностика и лечение новой коронавирусной инфекции 2019-nCoV». Временные методические рекомендации Министерства здравоохранения Российской Федерации. 2021; версия 12. Режим доступа: https://base.garant.ru/400738625/ Ссылка активна на 09.08.2022 [«Prevention, diagnosis and treatment of new coronavirus infection 2019-nCoV». Interim methodological recommendations of the Ministry of Health of the Russian Federation. 2021; version 12. Available at: https://base.garant.ru/400738625/ Accessed: 09.08.2022 (in Russian)].
2. Aggressive and defensive roles for chitinases
3. Lee CG, Da Silva CA, Cruz CSD, et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Ann Rev Physiol. 2011;73:1. DOI:0.1146/ANNUREV-PHYSIOL-012110-142250
4. Role of Chitotriosidase (Chitinase 1) Under Normal and Disease Conditions
5. Chitotriosidase: a marker and modulator of lung disease